Related Experiment Videos
Evaluating response to metrifonate
1Department of Psychiatry, University of Rochester Medical Center, NY 14620, USA.
Abstract:
Metrifonate, administered orally to patients with probable Alzheimer's disease in a once-daily dose, readily enters the brain and inhibits brain acetylcholinesterase (AChE) activity in a dose-dependent fashion. Metrifonate is a prodrug, converted non-enzymatically to 2,2-dichlorovinyl dimethyl phosphate, a long-acting inhibitor of AChE that produces stable enzyme inhibition over time. In combination, these pharmacologic characteristics lead to a reduced side effect profile in comparison with several other cholinesterase inhibitors. Both preliminary and confirmatory pivotal studies have shown that significant cognitive improvement is achieved with this medication in comparison with placebo in patients with probable Alzheimer's disease. Moreover, these studies also have demonstrated that metrifonate benefits the global function--a measure comprising domains of cognition, function, activities of daily living, and behavior--of patients with Alzheimer's disease. The medication is generally well tolerated, and no significant laboratory abnormalities occur. Therefore, metrifonate is a useful treatment for the symptoms of Alzheimer's disease.
Insights
Metrifonate, an oral Alzheimer's disease medication, effectively inhibits acetylcholinesterase (AChE) in the brain. Studies show it significantly improves cognition and global function in patients with probable Alzheimer's disease.
Area of Science:
- Pharmacology and Neurology
- Neuroscience
- Geriatric Medicine
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- Acetylcholinesterase (AChE) inhibitors are a primary symptomatic treatment for AD.
- Existing AChE inhibitors may have dose-limiting side effects.
Purpose of the Study:
- To evaluate the efficacy and safety of metrifonate in patients with probable Alzheimer's disease.
- To assess metrifonate's pharmacokinetic and pharmacodynamic properties.
- To compare metrifonate's effects against a placebo.
Main Methods:
- Oral administration of metrifonate in a once-daily dose.
- Measurement of brain acetylcholinesterase (AChE) inhibition.
- Inclusion of preliminary and confirmatory pivotal studies.
- Assessment of cognitive function, global function, activities of daily living, and behavior.
Main Results:
- Metrifonate readily enters the brain and inhibits AChE in a dose-dependent manner.
- Significant cognitive improvement observed in metrifonate-treated patients compared to placebo.
- Metrifonate demonstrated benefits in global function, encompassing cognition, daily activities, and behavior.
- The medication is generally well tolerated with a reduced side effect profile.
Conclusions:
- Metrifonate is a prodrug converted to a long-acting AChE inhibitor.
- Metrifonate provides significant symptomatic benefits for patients with probable Alzheimer's disease.
- Metrifonate is a safe and effective treatment option for Alzheimer's disease symptoms.